121 related articles for article (PubMed ID: 1999003)
1. Pharmacokinetics of recombinant interferon alpha-C.
Merimsky O; Rubinstein M; Fischer D; Danon A; Chaitchik S
Cancer Chemother Pharmacol; 1991; 27(5):406-8. PubMed ID: 1999003
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog.
Gibson DM; Cotler S; Spiegel HE; Colburn WA
J Interferon Res; 1985; 5(3):403-8. PubMed ID: 4056487
[TBL] [Abstract][Full Text] [Related]
3. [A case of pulmonary metastasis from renal cell carcinoma in which complete remission was achieved by interferon therapy (r-IFN-alpha A, Ro 22-8181)].
Ishito N; Wada F; Aramaki K; Asano S; Johsen T
Gan To Kagaku Ryoho; 1986 Feb; 13(2):380-3. PubMed ID: 3947113
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of human recombinant interferon-beta in monkeys and rabbits.
Gomi K; Morimoto M; Inoue A; Kobayashi H; Deguchi T; Hara T; Nakamizo N
Gan; 1984 Mar; 75(3):292-300. PubMed ID: 6724230
[TBL] [Abstract][Full Text] [Related]
5. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study.
Fosså SD; Gunderson R; Moe B
Cancer; 1990 Jun; 65(11):2451-4. PubMed ID: 2337859
[TBL] [Abstract][Full Text] [Related]
7. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Figlin RA; deKernion JB; Mukamel E; Palleroni AV; Itri LM; Sarna GP
J Clin Oncol; 1988 Oct; 6(10):1604-10. PubMed ID: 3049952
[TBL] [Abstract][Full Text] [Related]
8. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
Kuzmits R; Scheithauer W; Ludwig H; Flener R
Acta Med Austriaca; 1985; 12(5):129-34. PubMed ID: 3938590
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of human recombinant interferon-alpha I after i.v. infusion and im injection in African green monkeys.
Wills RJ; Soike KF
J Interferon Res; 1988 Aug; 8(4):427-32. PubMed ID: 3171243
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of human lymphoblastoid interferon on advanced renal cell carcinoma.
Fujita T; Asano H; Naide Y; Ono Y; Ohshima S; Suzuki K; Aso Y; Ariyoshi Y; Fukushima M; Ota K
J Urol; 1988 Feb; 139(2):256-8. PubMed ID: 3339721
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma.
Naglieri E; Lopez M; Lelli G; Morelli F; Amodio A; Di Tonno P; Gebbia N; Di Seri M; Chetri MC; Rizzo P; Abbate I; Casamassima A; Selvaggi FP; Colucci G
Anticancer Res; 2002; 22(5):3045-51. PubMed ID: 12530040
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of recombinant alpha A interferon following I.V. infusion and bolus, I.M., and P.O. administrations to African green monkeys.
Wills RJ; Spiegel HE; Soike KF
J Interferon Res; 1984; 4(3):399-409. PubMed ID: 6491397
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of interferon treatment in patients with renal cell carcinoma and bladder carcinoma by oligo-A synthetase assay and determination of immunological parameters.
Grups JW; Komprecht B
J Biol Regul Homeost Agents; 1989; 3(3):98-101. PubMed ID: 2516404
[TBL] [Abstract][Full Text] [Related]
14. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of recombinant interferon alpha-2C in metastatic renal cell carcinoma.
Scheithauer W; Kuehrer I; Kutzmits R; Dittrich C; Steger G; Flener R; Ludwig H
J Biol Regul Homeost Agents; 1987; 1(2):81-6. PubMed ID: 3504086
[TBL] [Abstract][Full Text] [Related]
16. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects.
Rinehart JJ; Young D; Laforge J; Colborn D; Neidhart JA
Cancer Res; 1987 May; 47(9):2481-5. PubMed ID: 3567933
[TBL] [Abstract][Full Text] [Related]
18. [Comparative clinical study of single and combination therapy of human lymphoblastoid interferon (HLBI) with 5-FU in the treatment of advanced renal cell carcinoma].
Asakawa M; Maekawa T; Umeda M; Sakamoto W; Senju M; Iseki T; Nakatani T; Tanaka H; Horii A; Yamamoto K
Hinyokika Kiyo; 1989 Aug; 35(8):1451-5. PubMed ID: 2816609
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report.
Quesada JR; Swanson DA; Gutterman JU
J Clin Oncol; 1985 Aug; 3(8):1086-92. PubMed ID: 4020410
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers.
Buchwalder PA; Buclin T; Trinchard I; Munafo A; Biollaz J
J Interferon Cytokine Res; 2000 Oct; 20(10):857-66. PubMed ID: 11054273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
